Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published Date: Dec 13, 2016

Abstract

BACKGROUND: In recent years, a small but increasing number of neurologists choose to extend dose intervals of natalizumab with the aim of reducing the risk of progressive multifocal leukoencephalopathy (PML). This idea is based on the hypothesis that high drug concentrations increase the risk of PML.

Authors

  • Zoé LE van Kempen
    Department of Neurology, Neuroscience Campus Amsterdam, VUmc MS Center Amsterdam, VU University Medical Center Amsterdam, Amsterdam, The Netherlands.
  • Cyra E Leurs
    Department of Neurology, Neuroscience Campus Amsterdam, VUmc MS Center Amsterdam, VU University Medical Center Amsterdam, Amsterdam, The Netherlands.
  • Anke Vennegoor
    Department of Neurology, Neuroscience Campus Amsterdam, VUmc MS Center Amsterdam, VU University Medical Center Amsterdam, Amsterdam, The Netherlands.
  • Mike P Wattjes
    Department of Radiology & Nuclear Medicine, Neuroscience Campus Amsterdam, VUmc MS Center Amsterdam, VU University Medical Center Amsterdam, Amsterdam, The Netherlands.
  • Theo Rispens
    Landsteiner Laboratory, Department of Immunology, Sanquin Research, Amsterdam, The Netherlands.
  • Bernard Mj Uitdehaag
    Department of Neurology, Neuroscience Campus Amsterdam, VUmc MS Center Amsterdam, VU University Medical Center Amsterdam, Amsterdam, The Netherlands.
  • Joep Killestein
    Department of Neurology, Neuroscience Campus Amsterdam, VUmc MS Center Amsterdam, VU University Medical Center Amsterdam, Amsterdam, The Netherlands.

Keywords

External Resources

Popular Topics
Recent Journals